top of page
  • Completed

NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency

Updated: Sep 27, 2022


NCT02045017: Phase 2: Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

pom-dex-myeloma

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency


The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple myeloma, with moderate or severe renal impairment.


Sponsor:

Celgene


Multiple Locations

International Study

Europe

 

ClinicalTrials.gov Identifier: NCT02045017

Official Title: A Phase 2 Multicenter, Open-label Study to Determine the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Moderate or Severe Renal Impairment Including Subjects Undergoing Hemodialysis

First Posted : January 24, 2014


Click here to see details on ClinicalTrials.gov

 

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Pomalidomide: National Cancer Institute

Pomalidomide : MedlinePlus Drug Information


Drug: Pomalidomide and Dexamethasone

 

J Clin Oncol; 2018

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

https://pubmed.ncbi.nlm.nih.gov/29394124/



Posts Archive
bottom of page